Marijuana and Medicinal Cannabis

    As of 1st May 2021, Epidyolex (cannabis-based medicine) has been approved by the TGA and is available via the Pharmaceutical Benefits Scheme (PBS) for the treatment of seizures associated with Dravet syndrome in patients ages 2 years and older:

    • PBS - Epidyolex (cannabidiol) for the treatment of seizures in Dravet Syndrome.
    • MIMS - Epidyolex product information

      Current literature

      There is now data from randomised controlled trials of the efficacy of Epidioloex in Dravet Syndrome, Lennox-Gastaut syndrome and Tuberous Sclerosis. 

      • Devinsky (2016) Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. N Engl J Med 376;21
      • Thiele et al. (2018) Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet, 391
      • Devinsky et al (2017). N. Engl J Med 2017;376:2011-20.
      • Devinsky et al (2018). Effect of Cannabidiol on Drop Seizures in the Lennox- Gastaut Syndrome. N Engl J Med 2018;378:1888-97.
      • Cannabidiol (CBD) treatment in patients with seizures associated with Tuberous Sclerosis Complex: A randomised, double-blind, placebo-controlled, placebo-controlled phase 3 trial (GWPCARE6) (Abst. 1.293), 2019

      In November 2016, the Epilepsy Society of Australia issued a position statement concerning Marijuana and Medicinal Cannabis in the treatment of epilepsy: